Open AccessDelaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis
Author(s) -
Georgios Chamilos,
Russell E. Lewis,
Dimitrios P. Kontoyiannis
Publication year - 2008
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/590004
Subject(s) - zygomycosis , medicine , amphotericin b , hematologic malignancy , odds ratio , malignancy , posaconazole , mucormycosis , confidence interval , surgery , mycosis , mortality rate , gastroenterology , antifungal , dermatology
Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom